Reshape Lifesciences Inc (RSLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Sales | 4,050 | 3,515 | 4,450 | 3,074 | 450 |
| Cost of Goods | 1,935 | 1,413 | 1,593 | 843 | 78 |
| Gross Profit | 2,115 | 2,102 | 2,857 | 2,231 | 372 |
| Operating Expenses | 6,164 | 8,133 | 14,933 | 7,320 | 4,566 |
| Operating Income | -3,114 | -5,618 | -11,483 | -4,246 | -4,116 |
| Interest Expense | 61 | 74 | 213 | 103 | 9 |
| Other Income | -22,189 | -23,062 | -4,810 | -127 | -22 |
| Pre-tax Income | -25,364 | -28,754 | -16,506 | -4,476 | -4,147 |
| Income Tax | -307 | N/A | -586 | N/A | -325 |
| Net Income Continuous | -25,057 | -28,754 | -15,920 | -4,476 | -3,822 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | -23,841 |
| Net Income | $-25,057 | $-28,754 | $-15,920 | $-4,476 | $-27,663 |
| EPS Basic Total Ops | 278.91 | -106.44 | -150.24 | -65.16 | 352,146.60 |
| EPS Basic Continuous Ops | 278.92 | -106.44 | -150.24 | -65.16 | 216,026.00 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | 136,120.50 |
| EPS Diluted Total Ops | 278.91 | -106.44 | -150.24 | -65.16 | 352,146.60 |
| EPS Diluted Continuous Ops | 278.92 | -106.44 | -150.24 | -65.16 | 216,026.00 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | 136,120.50 |
| EPS Diluted Before Non-Recurring Items | N/A | -17.36 | -101.21 | N/A | N/A |
| EBITDA(a) | $-2,693 | $-5,196 | $-4,465 | $-3,813 | $-3,987 |